APA (7th ed.) Citation

U, O., SA, E., S, S., I, S., O, B., E, A., . . . D, U. (2026). Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer regardless of platinum sensitivity. Anti-cancer drugs, 37(6), 359. https://doi.org/10.1097/CAD.0000000000001798

Chicago Style (17th ed.) Citation

U, Ozberk, Esen SA, Sekmek S, Seven I, Bal O, Algin E, Yucel S, and Uncu D. "Survival Advantage of Bevacizumab Rechallenge in Recurrent Ovarian Cancer Regardless of Platinum Sensitivity." Anti-cancer Drugs 37, no. 6 (2026): 359. https://doi.org/10.1097/CAD.0000000000001798.

MLA (9th ed.) Citation

U, Ozberk, et al. "Survival Advantage of Bevacizumab Rechallenge in Recurrent Ovarian Cancer Regardless of Platinum Sensitivity." Anti-cancer Drugs, vol. 37, no. 6, 2026, p. 359, https://doi.org/10.1097/CAD.0000000000001798.